L. Lam

发表

Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia

R. Galetto, G. Roboz, J. Smith, 2018, Leukemia & lymphoma.

Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.

S. Tagawa, B. Leach, G. Galletti, 2017, Cancer treatment reviews.

Antibody therapeutics for treating prostate cancer: where are we now and what comes next?

P. Vlachostergios, S. Tagawa, Beerinder S. Karir, 2017, Expert opinion on biological therapy.

Differential cellular responses induced by dorsomorphin and LDN‐193189 in chemotherapy‐sensitive and chemotherapy‐resistant human epithelial ovarian cancer cells

S. Gibson, M. Nachtigal, T. Werbowetski-Ogilvie, 2015, International journal of cancer.

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia

J. Scandura, P. Christos, G. Roboz, 2018, Haematologica.

Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer

H. Beltran, S. Vallabhajosula, N. Bander, 2019, Cancer.

Final results of 2-dose fractionation of 177Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).

H. Beltran, S. Vallabhajosula, N. Bander, 2016 .

Interleukin 2 Receptor-α (CD25) Expression Is Associated with Shortened Overall Survival and Resistance to Induction Therapy with Plerixafor and Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

J. Scandura, Wen Xie, G. Roboz, 2014 .

MP50-19 DOSE-FRACTIONATED ANTI-PSMA RADIOIMMUNOTHERAPY (177LU-J591) FOR MCRPC

H. Beltran, S. Vallabhajosula, N. Bander, 2016 .